NCR Online Journal

DDA Platform Releases In Vitro and In Vivo ADME Services to Adapt the Different Stages of the Drug Development Process

 Breaking News
  • No posts were found

DDA Platform Releases In Vitro and In Vivo ADME Services to Adapt the Different Stages of the Drug Development Process

May 14
02:02 2021
In Creative Bioarray, the professional team is dedicated to providing comprehensive in vivo and in vitro ADME services for drug discovery organizations, adapting to the different stages of the drug development process.

New York, USA – May 13, 2021 – DDA platform, the professional platform of Creative Bioarray, focuses on developing unique technologies and cutting-edge products to satisfy the needs of clients across numerous countries and districts. In Creative Bioarray, the professional team is dedicated to providing comprehensive in vivo and in vitro ADME services for drug discovery organizations, adapting to the different stages of the drug development process.

In Creative Bioarray, the professional DMPK department provides high-quality services and provides a wide range of standard in vitro and in vivo assay methods covering the early discovery stage and more advanced compound profile analysis. Conducting in vivo PK/PD efficacy studies in preclinical models can provide researchers with quantitative analysis of dose-response relationships, describing and predicting the effect of one or more drug doses on time course. Understand the frequency and degree of target adjustment to observe statistically significant efficacy and determine an effective dosing regimen with an acceptable therapeutic index.

PK/PD analysis is a key aspect of drug development, understanding the bioavailability, exposure, half-life, clearance, and metabolism of a drug may determine clinical success or failure. Creative Bioarray provides in vivo PK/PD services by leveraging extensive expertise and models to support drug discovery and preclinical development of small molecules, peptides, nucleosides/nucleotides and biological agents. All life work of PK/PD research is carried out in AAALAC-approved animal facilities and follows the procedures approved by IACUC.

Creative Bioarray provides comprehensive in vitro ADME services for drug discovery organizations. Analysis methods include multiple formats to adapt to different stages of the drug development process, enabling Creative Bioarray to provide flexible methods for ADME services. The experienced research team can also help design customized best strategies and programs to meet any drug discovery needs. Available ADME services include lipophilicity and solubility, in vitro permeability, plasma stability determination, CYP inhibition, non-CYP-mediated metabolism, and metabolite identification.

“Creative Bioarray has a team of passionate scientists with rich industry experience in drug discovery and development, which can help timely research design, data interpretation, research planning and execution.” said Hannah Cole, the marketing director of Creative Bioarray, she also said, “Our well-trained and experienced scientific team provides clients with extensive and in-depth expertise in appropriate research design, research execution, and data interpretation. We also provide extensive drug metabolism and pharmacokinetic functions for new chemical entities and compounds under development.”

About Creative Bioarray

Founded in 2005, Creative Bioarray is dedicated to offering customers with innovative biotechnology products and services for research use to greatly enhance and drive innovation and standards in science. As a well-recognized industry leader with more than 10 years of experience and in-house experts supported, Creative Bioarray has already countenanced research all around the world.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-386-8241
Country: United States
Website: https://dda.creative-bioarray.com